The painful ankle and foot joints in patients with Rheumatoid arthritis Hyaluronic acid,
Conditions
Interventions
Ultrasoind guided inejction of Hyaluronic acid to ankle and foot joint ,Ultrasoind guided inejction of Lidocaine to ankle and foot joint
Experimental Drug,Placebo Comparator Drug
hyaluronic acid,Lidocaine
Sponsors
Chen-Liang Chou
Chen-
Liang Chou
Eligibility
Sex/Gender
All
Age
35 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1)diagnosed with RA that met the ACR criteria28 for RA classification; 2)were aged>18years; 3)had a disease duration of at least 1year;4)had no ankle or foot joint deformity or ankylosis; and 5)had no active disease flare-up or other substantial ongoing active diseases,such as infections, and had a stable condition within 6 months. The disease activity was measured using disease activity scores-28 (DAS28).The level of disease activity can be interpreted as remission (DAS28≦2.6), low (2.65.1),according to the European League Against Rheumatism(EULAR) response criteria.
Exclusion criteria
Exclusion criteria: Patients were excluded if their treatment needed to be changed immediately; if they had changed their treatment protocol within 1 month; if they had substantial active diseases, such as infections, or a history of allergy to lidocaine (LI) or HA injection ;or if they had a history of traumatic ankle or foot injury with bone destruction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Foot function index ,VAS baseline 2nd week 4th week By asking patients,color flow doppler baseline 2nd week 4th week Ultrasound | — |
Secondary
| Measure | Time frame |
|---|---|
| Prevalence of pulmonary hypertension among patients with valvular heart disease undergoing surgery 1 year Review from echocardiographic report | — |
Countries
TAIWAN
Contacts
Public ContactChien-Chih Wang
Department of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital
Outcome results
None listed